Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT)

被引:17
|
作者
Thom, George [1 ]
McIntosh, Alasdair [2 ]
Messow, Claudia-Martina [2 ]
Leslie, Wilma S. [1 ]
Barnes, Alison C. [3 ]
Brosnahan, Naomi [1 ]
McCombie, Louise [1 ]
Malkova, Dalia [1 ]
Al-Mrabeh, Ahmad [4 ]
Zhyzhneuskaya, Sviatlana [4 ]
Welsh, Paul [5 ]
Sattar, Naveed [5 ]
Taylor, Roy [4 ]
Lean, Michael E. J. [1 ]
机构
[1] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow Royal Infirm, Human Nutr,Sch Med Dent & Nursing, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Glasgow, Inst Hlth & Wellbeing, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[3] Newcastle Univ, Inst Hlth & Soc, Human Nutr Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England
[4] Newcastle Univ, Inst Cellular Med, Newcastle Magnet Resonance Ctr, Newcastle Upon Tyne, Tyne & Wear, England
[5] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
关键词
obesity; diet; weight regain; appetite hormones; PLASMA GHRELIN; PEPTIDE YY; LOSS MAINTENANCE; ACUTE EXERCISE; BODY-WEIGHT; FOOD-INTAKE; APPETITE; OBESE; TERM; ADAPTATIONS;
D O I
10.1111/dom.14274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim To investigate whether appetite-related hormones were predictors of weight regain in the Diabetes Remission Clinical Trial (DiRECT). Materials and Methods DiRECT is a cluster-randomized clinical trial, designed to assess the effect of weight loss on type 2 diabetes remission. For this post hoc analysis, data were available for 253 (147 interventions, 106 controls) individuals with type 2 diabetes (age 53.6 +/- 7.5 years, body mass index 34.7 +/- 4.4 kg/m(2), 59% men). Intervention participants received a 24-month weight management programme, and controls remained on usual diabetes care. Fasting plasma concentrations of leptin, ghrelin, glucagon-like peptide-1 and peptide YY were measured at baseline, 12 months and 24 months in all participants, and at 5 months in a subset of participants in the intervention (n = 56) and control groups (n = 22). Potential predictors were examined using multivariable linear regression models. Results The intervention group lost 14.3 +/- 6.0% body weight at 5 months but regained weight over time, with weight losses of 10.0 +/- 7.5% at 12 months and 7.6 +/- 6.3% at 24 months. Weight loss in controls was 1.1 +/- 3.7% and 2.1 +/- 5.0% at 12 and 24 months, respectively. Body weight increased by 2.3% (95% confidence interval [CI] 0.4, 4.1; P = 0.019) between 12 and 24 months for every 1-ng/mL increase in ghrelin between baseline and 12 months, and weight regain between 12 and 24 months was increased by 1.1% (95% CI 0.2, 2.0; P = 0.023) body weight for every 1-ng/mL increase in ghrelin at 12 months. Conclusion The rise in ghrelin (but not any other measured hormone) during diet-induced weight loss was a predictor of weight regain during follow-up, and concentrations remained elevated over time, suggesting a small but significant compensatory drive to regain weight. Attenuating the effects of ghrelin may improve weight-loss maintenance.
引用
收藏
页码:711 / 719
页数:9
相关论文
共 12 条
  • [1] The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT)
    Corbin, Laura J.
    Hughes, David A.
    Bull, Caroline J.
    Vincent, Emma E.
    Smith, Madeleine L.
    McConnachie, Alex
    Messow, Claudia-Martina
    Welsh, Paul
    Taylor, Roy
    Lean, Michael E. J.
    Sattar, Naveed
    Timpson, Nicholas J.
    DIABETOLOGIA, 2024, 67 (01) : 74 - 87
  • [2] Brief formula low-energy-diet for relapse management during weight loss maintenance in the Diabetes Remission Clinical Trial (DiRECT)
    Brosnahan, Naomi
    Leslie, Wilma
    McCombie, Louise
    Barnes, Alison
    Thom, George
    McConnachie, Alex
    Messow, Claudia Martina
    Sattar, Naveed
    Taylor, Roy
    Lean, Michael E. J.
    JOURNAL OF HUMAN NUTRITION AND DIETETICS, 2021, 34 (03) : 472 - 479
  • [3] Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial
    Wing, Rena R.
    Espeland, Mark A.
    Clark, Jeanne M.
    Hazuda, Helen P.
    Knowler, William C.
    Pownall, Henry J.
    Unick, Jessica
    Wadden, Thomas
    Wagenknecht, Lynne
    DIABETES CARE, 2016, 39 (08) : 1345 - 1355
  • [4] 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study
    Lean, Michael E. J.
    Leslie, Wilma S.
    Barnes, Alison C.
    Brosnahan, Naomi
    Thom, George
    McCombie, Louise
    Kelly, Tara
    Irvine, Keaton
    Peters, Carl
    Zhyzhneuskaya, Sviatlana
    Hollingsworth, Kieren G.
    Adamson, Ashley J.
    Sniehotta, Falko F.
    Mathers, John C.
    McIlvenna, Yvonne
    Welsh, Paul
    McConnachie, Alex
    McIntosh, Alasdair
    Sattar, Naveed
    Taylor, Roy
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (04) : 233 - 246
  • [5] Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial
    Thomsen, Mads N.
    Skytte, Mads J.
    Samkani, Amirsalar
    Carl, Martin H.
    Weber, Philip
    Astrup, Arne
    Chabanova, Elizaveta
    Fenger, Mogens
    Frystyk, Jan
    Hartmann, Bolette
    Holst, Jens J.
    Larsen, Thomas M.
    Madsbad, Sten
    Magkos, Faidon
    Thomsen, Henrik S.
    Haugaard, Steen B.
    Krarup, Thure
    DIABETOLOGIA, 2022, 65 (03) : 506 - 517
  • [6] Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial
    Mads N. Thomsen
    Mads J. Skytte
    Amirsalar Samkani
    Martin H. Carl
    Philip Weber
    Arne Astrup
    Elizaveta Chabanova
    Mogens Fenger
    Jan Frystyk
    Bolette Hartmann
    Jens J. Holst
    Thomas M. Larsen
    Sten Madsbad
    Faidon Magkos
    Henrik S. Thomsen
    Steen B. Haugaard
    Thure Krarup
    Diabetologia, 2022, 65 : 506 - 517
  • [7] Clinical utility of liver function tests for resolution of metabolic dysfunction-associated steatotic liver disease after weight loss in the Diabetes Remission Clinical Trial
    Zhyzhneuskaya, S. V.
    Al-Mrabeh, A. H.
    Peters, C.
    Barnes, A. C.
    Hollingsworth, K. G.
    Welsh, P.
    Sattar, N.
    Lean, M. E. J.
    Taylor, R.
    DIABETIC MEDICINE, 2025, 42 (03)
  • [8] Comparison of weight loss induced by daily caloric restriction versus intermittent fasting (DRIFT) in individuals with obesity: study protocol for a 52-week randomized clinical trial
    Ostendorf, Danielle M.
    Caldwell, Ann E.
    Zaman, Adnin
    Pan, Zhaoxing
    Bing, Kristen
    Wayland, Liza T.
    Creasy, Seth A.
    Bessesen, Daniel H.
    MacLean, Paul
    Melanson, Edward L.
    Catenacci, Victoria A.
    TRIALS, 2022, 23 (01)
  • [9] Prediction of Cardiometabolic Health Through Changes in Plasma Proteins With Intentional Weight Loss in the DiRECT and DIADEM-I Randomized Clinical Trials of Type 2 Diabetes Remission
    Sattar, Naveed
    Taheri, Shahrad
    Astling, David P.
    Chadwick, Jessica
    Hinterberg, Michael A.
    Holmes, Michael V.
    Troth, Emma V.
    Welsh, Paul
    Zaghloul, Hadeel
    Chagoury, Odette
    Lean, Mike
    Taylor, Roy
    Williams, Steve
    DIABETES CARE, 2023, 46 (11) : 1949 - 1957
  • [10] Very low-energy and low-energy formula diets: Effects on weight loss, obesity co-morbidities and type 2 diabetes remission - an update on the evidence for their use in clinical practice
    Brown, A.
    Leeds, A. R.
    NUTRITION BULLETIN, 2019, 44 (01) : 7 - 24